Carly Fabrizio

Carly Fabrizio

Auto-generated profile, based on publicly available information

Carly Fabrizio

Christiana Care Health Services Inc

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2021 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
PDF file
CFCarly Fabrizio
Carly Fabrizio
MLMarissa N Levito
Marissa N Levito
RRRyan Rivosecchi
Ryan Rivosecchi
MBMichael Bashline
Michael Bashline
BSBrittany Slocum
Brittany Slocum
EHEdward T Horn
Edward T Horn
Temporary mechanical circulatory support (tMCS) devices are used for the management of cardiogenic shock. The Impella 5.0 (Abiomed; Danvers, MA) (IMP5) is a commonly used, surgically implanted, tMCS device that requires systemic anticoagulation and purge solution to avoid pump failure. To avoid heparin-induced thrombocytopenia (HIT) from unfractionated heparin (UFH) use, our program has explored the utility of bivalirudin (BIV) for systemic anticoagulation in IMP5. This single center, retrospective study included patients supported on IMP5 with BIV based AC. The efficacy and safety end points were recovery, bridge to left ventricular assist device (LVAD), cardiac transplant (HTX), or death as well as clinically significant bleeding, incidence of Tissue Plasminogen Activator (tPA) use for suspected pump thrombosis, stroke, and device failure. There were 31 patients included, and 26 (84%) received BIV purge solutions. The median duration of IMP5 was 6 (IQR 4–10) days. Most patients were bridged to LVAD (39%, 12); 16% (5) were bridged to HTX, 16% (5) recovered, and 29% (9) died. One patient (3%) suffered from ischemic stroke and 12% (4) patients developed clinically significant bleeding. tPA was administered to 8 (26%) patients. Logistic regression analysis demonstrated that duration of IMP5 was a significant predictor of tPA use (OR 1.28; 95% Confidence Interval 1.04–1.56). There were no cases of pump failure. Our experience highlights the feasibility of utilizing BIV for routine AC use in IMP5.

1 April 2021 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
CFC. Fabrizio
C. Fabrizio
GHG. Hickey
G. Hickey
RRR. Ramani
R. Ramani

29 December 2021
Verified
Preprint
Open access
PDF file
NHNicholas Ryan Hess
Nicholas Ryan Hess
MKMary Keebler
Mary Keebler
CFCarly A. Fabrizio
Carly A. Fabrizio
DKDavid Kaczorowski
David Kaczorowski
Anomalous coronary arteries arise in a small subset of the population, with each configuration conveying a varying degree of long-term risk. In this report, we describe the discovery of an anomalous single coronary artery with the left main coronary artery arising from the right coronary ostium in a 40-year old male evaluated for cardiac donation. After evaluation, this heart was successfully procured and utilized for orthotopic heart transplantation.